Led by the Front Line COVID-19 Critical Care Alliance (FLCCC), a group of medical and scientific experts reviewed published peer-reviewed studies, manuscripts, expert meta-analyses, and epidemiological analyses of regions with ivermectin distribution efforts all showing that ivermectin is an effective prophylaxis and treatment for COVID-19.
‘The ivermectin distribution campaigns repeatedly led to rapid population-wide decreases in morbidity and mortality.’
“We did the work that the medical authorities failed to do, we conducted the most comprehensive review of the available data on ivermectin,” said Pierre Kory, MD, president and chief medical officer of the FLCCC.
“We applied the gold standard to qualify the data reviewed before concluding that ivermectin can end this pandemic.”
A focus of the manuscript was on the 27 controlled trials available in January 2021, 15 of which were randomised controlled trials (RCT’s).
Consistent with numerous meta-analyses of ivermectin RCT’s since published by expert panels from the UK, Italy, Spain and Japan, they found large, statistically significant reduction in mortality, time to recovery and viral clearance in Covid-19 patients treated with ivermectin.
“Our latest research shows, once again, that when the totality of the evidence is examined, there is no doubt that ivermectin is highly effective as a safe prophylaxis and treatment for Covid-19,” said Paul E. Marik, founding member of the FLCCC and Chief, Pulmonary and Critical Care Medicine at Eastern Virginia Medical School.
Many regions around the world now recognise that ivermectin is a powerful prophylaxis and treatment for Covid-19.
South Africa, Zimbabwe, Slovakia, Czech Republic, Mexico, and India have approved the drug for use by medical professionals.
“We are calling on regional public health authorities and medical professionals around the world to demand that ivermectin be included in their standard of care right away so we can end this pandemic once and for all,” Marik noted.
Source: IANS
